Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Dec;8(12):1700-1714.
doi: 10.1038/s41551-024-01240-4. Epub 2024 Jul 22.

Reprogramming human B cells with custom heavy-chain antibodies

Affiliations

Reprogramming human B cells with custom heavy-chain antibodies

Geoffrey L Rogers et al. Nat Biomed Eng. 2024 Dec.

Abstract

The immunoglobulin locus of B cells can be reprogrammed by genome editing to produce custom or non-natural antibodies that are not induced by immunization. However, current strategies for antibody reprogramming require complex expression cassettes and do not allow for customization of the constant region of the antibody. Here we show that human B cells can be edited at the immunoglobulin heavy-chain locus to express heavy-chain-only antibodies that support alterations to both the fragment crystallizable domain and the antigen-binding domain, which can be based on both antibody and non-antibody components. Using the envelope protein (Env) from the human immunodeficiency virus as a model antigen, we show that B cells edited to express heavy-chain antibodies to Env support the regulated expression of B cell receptors and antibodies through alternative splicing and that the cells respond to the Env antigen in a tonsil organoid model of immunization. This strategy allows for the reprogramming of human B cells to retain the potential for in vivo amplification while producing molecules with flexibility of composition beyond that of standard antibodies.

PubMed Disclaimer

Conflict of interest statement

Competing interests: The authors declare no competing interests.

Update of

References

    1. Qerqez, A. N., Silva, R. P. & Maynard, J. A. Outsmarting pathogens with antibody engineering. Annu. Rev. Chem. Biomol. Eng. 14, 217–241 (2023). - PubMed - PMC - DOI
    1. Carter, P. J. & Rajpal, A. Designing antibodies as therapeutics. Cell 185, 2789–2805 (2022). - PubMed - DOI
    1. Page, A., Fusil, F. & Cosset, F. L. Towards physiologically and tightly regulated vectored antibody therapies. Cancers 12, 962 (2020). - PubMed - PMC - DOI
    1. Zhan, W., Muhuri, M., Tai, P. W. L. & Gao, G. Vectored immunotherapeutics for infectious diseases: can rAAVs be the game changers for fighting transmissible pathogens? Front. Immunol. 12, 673699 (2021). - PubMed - PMC - DOI
    1. Martinez-Navio, J. M. et al. Long-term delivery of an anti-SIV monoclonal antibody with AAV. Front. Immunol. 11, 449 (2020). - PubMed - PMC - DOI

MeSH terms

Substances

LinkOut - more resources